Half Year 2026 Telix Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Telix Pharmaceuticals Ltd (TLPPF) delivered strong financial results with revenue up 22% year-on-year to $477 million and EBITDA improving 146% to $52 million.
- The Precision Medicine business saw robust growth of 27% year-on-year, driven by successful launches of Gozellix and continued strength of Illuccix, with market share increasing for 16 consecutive quarters.
- Regulatory progress is on track with Pixclara assigned a PDUFA date of September 11, 2026, and submissions completed for Pixclara and Pixlumi in both the US and Europe.
- The BiPASS Phase 3 study, which could potentially double the PSMA imaging market, is close to completing targeted enrollment, with strong physician enthusiasm and rapid recruitment.
- The company maintains a strong cash position of $252 million after refinancing convertible bonds on better terms, providing financial capacity to accelerate growth.
- Telix Pharmaceuticals Ltd (TLPPF) is advancing a diversified therapeutic pipeline with three Phase 3 candidates, including ProstACT Global, IPAX BrIGHT, and LUTEON, and has a strategic collaboration with Regeneron for next-generation alpha therapies.
- International expansion is progressing well, with NDA submissions in China and Japan, and the company is building infrastructure for future therapeutic launches.
- Zircaix received a corrected Complete Response Letter from the FDA, and the resubmission process is still ongoing, with no definitive timeline for approval.
- The company maintains conservative full-year revenue guidance of $950-$970 million despite strong performance, suggesting potential headwinds or uncertainty in the second half.
- R&D investment increased significantly, representing 26% of revenue, which may pressure near-term profitability despite strong commercial performance.
- The PSMA imaging market is estimated to be nearly two-thirds penetrated, limiting future growth potential in the core diagnostic segment.
- Competitive threats loom with Lantheus's TruVu product receiving a reimbursement code, which could impact market share dynamics in the PSMA imaging space.
- The company faces regulatory delays and administrative issues with the FDA, as seen with the Zircaix CRL, which could affect investor confidence.
- The BiPASS trial's statistical powering was increased, raising questions about the robustness of the study design and potential challenges in meeting endpoints.
Good morning and good evening, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix, and it's my pleasure to welcome you today to our H1 2026 Interim Results Presentation and Call. You'll have seen our documents lodged on the ASX earlier this morning. Next slide, please.
Today on our call, we'll be joined by Dr. Christian Behrenbruch, Managing Director and Group CEO; Darren Smith, our Group Chief Financial Officer; Kevin Richardson, CEO of the Telix Precision Medicine business; and Dr. David Cade, Chief Medical Officer. Following prepared remarks, we will open up the call to Q&A, starting with calls on the conference line. If we don't get to your questions during the call, we'll respond to you after the call is finished. Just to move to the next slide, please.
Brief notice, but please note that today's presentation includes forward-looking statements, including within the meaning of the US Private Securities
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
